Local Therapy Combined With First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients With EGFR-Mutant Metastatic Non-Small Cell Lung Cancer.
Lu X, Wang J, Wang C, Liang J, Zhou Z, Chen D, Feng Q, Xiao Z, Hui Z, Lu J, Zhang T, Liu W, Wang J, Wang X, Deng L, Zhai Y, Bi N, Wang L.
Lu X, et al.
Clin Med Insights Oncol. 2022 Feb 26;16:11795549221080347. doi: 10.1177/11795549221080347. eCollection 2022.
Clin Med Insights Oncol. 2022.
PMID: 35250326
Free PMC article.